Edgewise Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
1715 38TH ST, BOULDER, CO, 80301
Mailing Address
1715 38TH ST, BOULDER, CO, 80301
Phone
720-262-7002
Fiscal Year End
1231
EIN
821725586
Financial Overview
FY2025
$552.60M
Total Assets
$522.26M
Stockholders' Equity
$61.15M
Cash & Equivalents
$-1.45
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| 4 Insider stock transaction report | March 30, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| 10-K Annual financial report | February 26, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | November 24, 2025 | View on SEC |
Insider Trading
STRONG SELL
2 insiders
9 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.